CALL: (661) 257-8400

Laser Hair Removal

Never Wax or Shave Again

Experience permanent reduction of unwanted hair anywhere on the body.

CALL NOW!

Best for treating:

Legs

Underarms

Bikini

Body

Shaving is time consuming and leaves behind coarse stubble, knicks and bumps. Waxing is painful and requires expensive monthly upkeep.

Depilatory creams are smelly and can irritate our skin. Electrolysis involves inserting a needle into each hair follicle one at a time and is outdated, tedious, and invasive.

Laser hair removal is the perfect modern alternative! State-of-the-art laser light technology allows us to permanently destroy hair follicles, reducing hair growth anywhere on the body.

Save time, save money and kiss ingrown hairs and razor burn goodbye forever. Treatments are safe and effective for all skin types and most patients achieve satisfactory results with just 5 sessions.

Before Laser Hair Removal
After Laser Hair Removal

"Laser hair removal was the best thing I ever did. So easy, so convenient and now my skin is smooth, hairless, and baby soft always."
- M.D.

Expert Tip

Most patients consider this treatment to be nearly painless due to our use of the Zimmer Cooler. We also offer nitrous oxide to completely eliminate pain for more sensitive patients.

Dr. Ingber, M.D.

Dermacure is an aesthetic medical office owned and operated by Craig Ingber, MD a board certified Facial Plastic Surgeon.

Dr. Ingber is a clinical instructor of surgery at UCLA Medical School and performs all injections upon request. He is a top 1% injector of Botox and Juvederm in the nation and is the #1 physician injector in Santa Clarita Valley.

LEARN MORE ABOUT DR. INGBER

Unwanted hair can now be a thing of the past with noninvasive laser hair removal.

Read More

KYBELLA® (deoxycholic acid) injection 10 mg/mL Important Information

INDICATION
KYBELLA® (deoxycholic acid) injection is indicated for improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults.

The safe and effective use of KYBELLA® for the treatment of subcutaneous fat outside the submental region has not been established and is not recommended.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS 
KYBELLA® is contraindicated in the presence of infection at the injection sites.

WARNINGS AND PRECAUTIONS
Marginal Mandibular Nerve Injury
Cases of marginal mandibular nerve injury, manifested as an asymmetric smile or facial muscle weakness, were reported in 4% of subjects in the clinical trials; all cases resolved spontaneously (range 1-298 days, median 44 days). KYBELLA® should not be injected into or in close proximity to the marginal mandibular branch of the facial nerve.

Dysphagia
Dysphagia occurred in 2% of subjects in the clinical trials in the setting of administration-site reactions, eg, pain, swelling, and induration of the submental area; all cases of dysphagia resolved spontaneously (range 1-81 days, median 3 days). Avoid use of KYBELLA® in patients with current or prior history of dysphagia as treatment may exacerbate the condition.

Injection-Site Hematoma/Bruising
In clinical trials, 72% of subjects treated with KYBELLA® experienced hematoma/bruising. KYBELLA® should be used with caution in patients with bleeding abnormalities or who are currently being treated with antiplatelet or anticoagulant therapy as excessive bleeding or bruising in the treatment area may occur.

Risk of Injecting Into or in Proximity to Vulnerable Anatomic Structures
To avoid the potential of tissue damage, KYBELLA® should not be injected into or in close proximity (1 cm-1.5 cm) to salivary glands, lymph nodes, and muscles.

Injection Site Alopecia
Cases of injection site alopecia have been reported with administration of KYBELLA®. Onset and duration may vary among individuals and may persist. Consider withholding subsequent treatments until resolution.

Injection Site Ulceration and Necrosis
Injections that are too superficial into the dermis may result in skin ulceration and necrosis. Cases of injection site ulceration and necrosis have been reported with administration of KYBELLA®. Do not administer KYBELLA® into affected area until complete resolution.

ADVERSE REACTIONS
The most commonly reported adverse reactions in the pivotal clinical trials were: injection site edema/swelling, hematoma/bruising, pain, numbness, erythema, and induration.

Please see KYBELLA® full Prescribing Information.

*Individual results may vary.
Call Us Today! 661-257-8400

Exfoliate dull, damaged skin to reveal youthful and glowing skin today!

Read More

KYBELLA® (deoxycholic acid) injection 10 mg/mL Important Information

INDICATION
KYBELLA® (deoxycholic acid) injection is indicated for improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults.

The safe and effective use of KYBELLA® for the treatment of subcutaneous fat outside the submental region has not been established and is not recommended.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS 
KYBELLA® is contraindicated in the presence of infection at the injection sites.

WARNINGS AND PRECAUTIONS
Marginal Mandibular Nerve Injury
Cases of marginal mandibular nerve injury, manifested as an asymmetric smile or facial muscle weakness, were reported in 4% of subjects in the clinical trials; all cases resolved spontaneously (range 1-298 days, median 44 days). KYBELLA® should not be injected into or in close proximity to the marginal mandibular branch of the facial nerve.

Dysphagia
Dysphagia occurred in 2% of subjects in the clinical trials in the setting of administration-site reactions, eg, pain, swelling, and induration of the submental area; all cases of dysphagia resolved spontaneously (range 1-81 days, median 3 days). Avoid use of KYBELLA® in patients with current or prior history of dysphagia as treatment may exacerbate the condition.

Injection-Site Hematoma/Bruising
In clinical trials, 72% of subjects treated with KYBELLA® experienced hematoma/bruising. KYBELLA® should be used with caution in patients with bleeding abnormalities or who are currently being treated with antiplatelet or anticoagulant therapy as excessive bleeding or bruising in the treatment area may occur.

Risk of Injecting Into or in Proximity to Vulnerable Anatomic Structures
To avoid the potential of tissue damage, KYBELLA® should not be injected into or in close proximity (1 cm-1.5 cm) to salivary glands, lymph nodes, and muscles.

Injection Site Alopecia
Cases of injection site alopecia have been reported with administration of KYBELLA®. Onset and duration may vary among individuals and may persist. Consider withholding subsequent treatments until resolution.

Injection Site Ulceration and Necrosis
Injections that are too superficial into the dermis may result in skin ulceration and necrosis. Cases of injection site ulceration and necrosis have been reported with administration of KYBELLA®. Do not administer KYBELLA® into affected area until complete resolution.

ADVERSE REACTIONS
The most commonly reported adverse reactions in the pivotal clinical trials were: injection site edema/swelling, hematoma/bruising, pain, numbness, erythema, and induration.

Please see KYBELLA® full Prescribing Information.

*Individual results may vary.

I'm Interested!

Please contact me with more information on this procedure.

©2018 DermaCure Valencia | Web Design by Small Dog Creative